CLYM: Climb Bio Inc. Price to Sales
Climb Bio Inc (CLYM) previously faced liquidity shortages due to R&D expenses, as confirmed by the price-to-sales ratio. The current value of reflects the metric's balance on the chart. The company relies on third-party contractors for molecule synthesis while developing a comprehensive therapy system for immune disorders to achieve patient remission.
Metric breakdowns and analytics for Climb Bio, Inc. (CLYM)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Climb Bio Inc|CLYM - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Climb Bio, Inc|CLYM - Company Aggregate Debts|Debt to Book Capitalization Ratio Climb Bio Inc|CLYM - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Climb Bio|Quick Liquidity climbbio.com
- business earnings and investment ratios data:
CLYM - Net Profit|Company Profit Forecast Climb Bio Inc|CLYM - Price to Earnings Ratio|Projected Price to Earnings Ratio Climb Bio Inc.|CLYM - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Climb Bio Inc|CLYM - Operating profit EBITDA|Net earnings per share for the last four quarters Climb Bio|CLYM - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months climbbio.com|CLYM - Earnings growth in current year|Expected earnings per share growth for next year Climb Bio Inc
- total revenue and sales volume data:
General company analysis:climbbio.com CLYM
Investors are assessing the stability of Climb Bio Inc (CLYM) through the price-to-sales ratio, which determines the value of every dollar of the business's revenue. By analyzing the P/S multiple, one can correlate the current valuation with the potential for long-term margins driven by immunology patents and high demand inertia for continuous treatment.
Who Climb Bio Inc competes with
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Protagonist Corp (PTGX) - Market Cap to Revenue|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|KNSA (kiniksa.com) - Price-to-Revenue Ratio|GRFS (Grifols) - P/S Multiple|Adaptive Biotech (ADPT) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Celldex (CLDX)|Market Cap to Revenue Aurinia Corp AUPH|P/S Multiple BCRX (BioCryst)|veratx.com - Price-to-Revenue Ratio|DNTH: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PHVS (Pharvaris NV)|ABCL: P/S Multiple|TRML (Tourmaline) - Price-to-Revenue Ratio|PGEN (Precigen, Inc.) - P/S Multiple|pharming.com (PHAR) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Nektar Therapeutics Inc. (NKTR)|UPB - Price to Sales|Zenas Biopharma, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IMNM|Gossamer Bio, Inc. - P/S Multiple|Price-to-Revenue Coefficient kalvista.com KALV|Septerna (SEPN) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio PVLA|SVRA (Savara Corp) - P/S Multiple|Market Cap to Revenue Rigel Corp (RIGL)|P/S Multiple ANAB|Market Cap to Revenue astriatx.com ATXS|Price-to-Revenue Ratio enGene ENGN|RAPT Therapeutics Inc. - Price-to-Revenue Ratio|JBIO: Market Cap to Revenue|Price to Sales Aclaris Therapeutics, Inc|Kyverna Therapeutics (KYTX) - Price-to-Revenue Ratio|Market Cap to Revenue tizianalifesciences.com|Price-to-Revenue Ratio Cabaletta Bio|Ventyx Biosciences Inc. - Price-to-Sales Ratio|P/S Multiple THTX|AVTX (Avalo Therapeutics Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple ELDN (Eledon Pharmaceuticals)|P/S Multiple agenusbio.com AGEN|ZURA - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ATYR (aTyr Pharma Inc)|adagene.com (ADAG) - Price-to-Revenue Ratio|Market Cap to Revenue Ikena Oncology|STTK (Shattuck Labs Inc) - P/S Multiple|P/S Multiple Equillium Bio|Market Cap to Revenue CNTB (Connect Biopharma)|IMUX (immunic-therapeutics.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ATRA (Atara Bio)|Price-to-Revenue Coefficient InflaRx NV (IFRX)|XFOR - Price-to-Revenue Ratio|Adicet Bio (ACET) - Market Cap to Revenue|celularity.com (CELU) - Price-to-Revenue Ratio|Market Cap to Revenue INmune Bio Inc|Market Cap to Revenue BRNS|P/S Multiple Kezar Life Sciences Inc|Price-to-Revenue Ratio SAB Biotherapeutics (SABS)|akaritx.com - Market Cap to Revenue Ratio|P/S Multiple ENLV (Enlivex Therapeutics Ltd.)|Q32 Bio Inc (QTTB) - Price to Sales|GeoVax Labs Inc - P/S Multiple|Edesa Biotech Corp (EDSA) - Market Cap to Revenue|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|CARM (Carisma Therapeutics Inc.) - Price-to-Revenue Ratio|XTLB (XTL Biopharmaceuticals Ltd.) - P/S Multiple|Bolt Bio (BOLT) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|Market Cap to Revenue aptevotherapeutics.com APVO|P/S Multiple AIM (AIM ImmunoTech Inc.)|Aditxt Inc. - Price-to-Revenue Ratio|GRI: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio XRTX (XORTX Therapeutics Inc)|HIND: P/S Multiple|REVB (Revelation Biosciences Corp) - Price-to-Revenue Ratio|INDP (Indaptus Therapeutics) - P/S Multiple|scinai.com (SCNI) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio CalciMedica, Inc. (CALI)|AFMD - Price to Sales|Allakos - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio HOOK|IGM Bio - P/S Multiple|Price-to-Revenue Coefficient iteostherapeutics.com ITOS|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio TCBP|THRD (Third Harmonic Bio, Inc) - P/S Multiple
